The Regulatory History of Cannabis in Medicine
Cannabis did not begin as a counterculture product. It entered Western medicine in the nineteenth century, appeared in the U.S. Pharmacopeia by 1850, and was prescribed through normal pharmacy channels for decades.
Then policy shifted. The Marihuana Tax Act of 1937 restricted medical access. The Controlled Substances Act of 1970 placed cannabis in Schedule I, blocking most research and routine prescribing. Demand did not disappear. It just became illegal. Clinicians stepped back. State-level reforms began reopening medical access with California in 1996.
1
Discovery
Cannabis enters Western medicine, appears in the U.S. Pharmacopeia by 1850, prescribed through normal pharmacy channels for decades.
2
Restriction
The Marihuana Tax Act of 1937 and the Controlled Substances Act of 1970 block most research and routine prescribing. Demand redirects, not disappears.
3
Gray Market
Clinicians step back. Demand moves underground. A parallel market operates outside formal medicine.
4
Incremental Legitimization
State-level reforms begin reopening medical access with California in 1996. Commercial scale follows.
The Regulatory History of Peptides in Longevity Medicine
The peptide story starts with insulin in 1921. A century later, dozens of FDA-approved peptide drugs sit firmly in mainstream practice.
Then came GLP-1s. Exenatide was approved in 2005. Liraglutide in 2010. Semaglutide in 2017. What began as a diabetes medication became, by the early 2020s, one of the fastest-adopted drug classes in modern medicine — reshaping how healthcare systems, payers, and patients think about metabolic disease, obesity, and preventive care. The GLP-1 class alone is now a market measured in the tens of billions, with manufacturing capacity still racing to catch up with demand.
A second track developed more quietly. Over two decades, 503A compounding pharmacies and clinicians used compounded peptides — BPC-157, CJC-1295, Ipamorelin, thymosin alpha-1, TB-500, and others — where mechanistic rationale was plausible and bedside experience was ahead of large-scale trials.
In 2023, the FDA moved a group of peptides to Category 2 of the 503A bulks list, ending their eligibility for standard compounding. In 2024, PCAC declined to recommend adding several peptides to the approved list, citing limited U.S. outcomes data. In 2026, FDA signaled reconsideration of approximately a dozen substances, with meetings scheduled in July 2026 and February 2027.
The Story Is Still Being Written
GLP-1s are a reminder that when a peptide class does cross the full regulatory arc, the impact on medicine can be generational.
The two stories trace the same shape. A restriction event that redirects demand rather than eliminating it. A slow, uneven path toward reconsideration. — Regulatory Pattern Analysis
What the Cannabis and Peptide Stories Have in Common
The two stories trace the same shape. A scientific breakthrough. Decades of legitimate pharmacy use. A restriction event that redirects demand rather than eliminating it. Physicians practicing between observation and evolving regulation. A slow, uneven path toward reconsideration. The differences matter too and they are worth naming carefully.
What the FDA Peptide Reclassification Means for Longevity Physicians
Peptides, like cannabis, are one chapter in a longer story of emerging modalities. Others will follow. What does not change is our obligation as physicians. What can change — and what this community is built to change — is how prepared we are when the next chapter arrives.
Four things each of us can do, independent of where the regulation lands.
Read the full article and subscribe to the weekly Intelligence briefing →
Longevity medicine is moving fast. Every week, we bring you what matters: clinical insights, research signals, and perspectives from 1,000+ physicians across 68 countries. One newsletter. Built for the physicians shaping this field.
Editorial Disclaimer
This newsletter is published exclusively for licensed physicians and qualified healthcare professionals. It is not intended for consumers or patients.
All content is for continuing medical education and professional information purposes only. It reflects emerging research, science, and technology that may have implications for the practice of medicine. It does not constitute medical advice, clinical recommendations, or treatment guidance for any individual patient.
By reading this newsletter, you confirm that you are a licensed healthcare professional and that you will apply the information contained herein within the bounds of your clinical judgment, professional obligations, and applicable regulations.
If you are a patient or consumer reading this newsletter, please note that this content should not be used to make any health or medical decisions. Please consult your personal physician or a qualified healthcare provider for guidance specific to your situation.
Are Peptides the New Cannabis?
Are Peptides the New Cannabis?
Science evolves. Regulation evolves. Our professional obligation does not: protect patients and practice within the law using the best evidence available at the time.
The Regulatory History of Cannabis in Medicine
Cannabis did not begin as a counterculture product. It entered Western medicine in the nineteenth century, appeared in the U.S. Pharmacopeia by 1850, and was prescribed through normal pharmacy channels for decades.
Then policy shifted. The Marihuana Tax Act of 1937 restricted medical access. The Controlled Substances Act of 1970 placed cannabis in Schedule I, blocking most research and routine prescribing. Demand did not disappear. It just became illegal. Clinicians stepped back. State-level reforms began reopening medical access with California in 1996.
Discovery
Cannabis enters Western medicine, appears in the U.S. Pharmacopeia by 1850, prescribed through normal pharmacy channels for decades.
Restriction
The Marihuana Tax Act of 1937 and the Controlled Substances Act of 1970 block most research and routine prescribing. Demand redirects, not disappears.
Gray Market
Clinicians step back. Demand moves underground. A parallel market operates outside formal medicine.
Incremental Legitimization
State-level reforms begin reopening medical access with California in 1996. Commercial scale follows.
The Regulatory History of Peptides in Longevity Medicine
The peptide story starts with insulin in 1921. A century later, dozens of FDA-approved peptide drugs sit firmly in mainstream practice.
Then came GLP-1s. Exenatide was approved in 2005. Liraglutide in 2010. Semaglutide in 2017. What began as a diabetes medication became, by the early 2020s, one of the fastest-adopted drug classes in modern medicine — reshaping how healthcare systems, payers, and patients think about metabolic disease, obesity, and preventive care. The GLP-1 class alone is now a market measured in the tens of billions, with manufacturing capacity still racing to catch up with demand.
A second track developed more quietly. Over two decades, 503A compounding pharmacies and clinicians used compounded peptides — BPC-157, CJC-1295, Ipamorelin, thymosin alpha-1, TB-500, and others — where mechanistic rationale was plausible and bedside experience was ahead of large-scale trials.
In 2023, the FDA moved a group of peptides to Category 2 of the 503A bulks list, ending their eligibility for standard compounding. In 2024, PCAC declined to recommend adding several peptides to the approved list, citing limited U.S. outcomes data. In 2026, FDA signaled reconsideration of approximately a dozen substances, with meetings scheduled in July 2026 and February 2027.
The Story Is Still Being Written
GLP-1s are a reminder that when a peptide class does cross the full regulatory arc, the impact on medicine can be generational.
What the Cannabis and Peptide Stories Have in Common
The two stories trace the same shape. A scientific breakthrough. Decades of legitimate pharmacy use. A restriction event that redirects demand rather than eliminating it. Physicians practicing between observation and evolving regulation. A slow, uneven path toward reconsideration. The differences matter too and they are worth naming carefully.
What the FDA Peptide Reclassification Means for Longevity Physicians
Peptides, like cannabis, are one chapter in a longer story of emerging modalities. Others will follow. What does not change is our obligation as physicians. What can change — and what this community is built to change — is how prepared we are when the next chapter arrives.
Four things each of us can do, independent of where the regulation lands.
Educate
Stay Fluent in the Evidence Before the Marketing Arrives.
Stay fluent in the evidence, the mechanisms, and the regulatory framework that governs your practice. Emerging modalities reward physicians who understand the science before the marketing. longevitydocs™ exists to make that education continuous, peer-reviewed, and physician-led.
Ongoing · CommunityStay Updated
Regulatory Landscapes Shift on Their Own Timeline — Not Yours.
FDA, PCAC, state boards, and international bodies move on their own timelines. A community that tracks these changes in real time and translates them into clinical language protects every physician in it.
Regulatory · IntelligenceRun Research
The Data Gap Is Something a Physician Community Can Close.
Advisory committees declined several peptides in part because organized U.S. outcomes data was missing. Clinician-led registries, standardized data capture, and shared protocols turn individual bedside experience into evidence the next regulatory cycle can actually weigh.
Research · EvidenceOperate Legally and Ethically
This Is the Posture That Outlasts Any Regulatory Cycle.
Stay within the boundaries of current law. Careful patient selection. Informed consent. Transparent communication about what is known, what is unknown, and what may change. Documentation that holds up to scrutiny.
Compliance · EthicsRead the full article and subscribe to the weekly Intelligence briefing →
Longevity medicine is moving fast. Every week, we bring you what matters: clinical insights, research signals, and perspectives from 1,000+ physicians across 68 countries. One newsletter. Built for the physicians shaping this field.
About longevitydocs™ longevitydocs.™ is the world's leading longevity physician community. Over 1,000 doctors across 50+ countries united by a single conviction: every doctor should be a longevity doctor. We are building the infrastructure, education, and community physicians need to make longevity medicine their default practice.
This newsletter is published exclusively for licensed physicians and qualified healthcare professionals. It is not intended for consumers or patients.
All content is for continuing medical education and professional information purposes only. It reflects emerging research, science, and technology that may have implications for the practice of medicine. It does not constitute medical advice, clinical recommendations, or treatment guidance for any individual patient.
By reading this newsletter, you confirm that you are a licensed healthcare professional and that you will apply the information contained herein within the bounds of your clinical judgment, professional obligations, and applicable regulations.
If you are a patient or consumer reading this newsletter, please note that this content should not be used to make any health or medical decisions. Please consult your personal physician or a qualified healthcare provider for guidance specific to your situation.